The US Food and Drug Administration announced today that it has granted de novo authorization to two COVID-19 tests developed by QuidelOrtho Corporation subsidiary Ortho Clinical Diagnostics, making them the first serology tests for the virus to win full clearance from the FDA.
The products are the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack and the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack, both of which are used with the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Calibrator
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?